Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

IMDX vs SYBX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SYBX Captures Overall Composite Edge (34.6 SELL vs 45.5 HOLD), While IMDX Leads 3–2 on Growth & Valuation Pillars

SYBX Overall Winner 6-Pillar Tally: IMDX 3 – 2 SYBX (1 Tie) Matrix Metrics: IMDX 5 – 2 SYBX

As of Nov 19, 2026, Synlogic, Inc. (SYBX) captures the overall head-to-head institutional edge over Insight Molecular Diagnostics Inc. (IMDX) on higher Unified Composite conviction (34.6/100 SELL vs. 45.5/100 HOLD) after splitting the core matrix 2–5 (led by Profitability & Quality, Options & Positioning), while IMDX wins 3–2 across the 6-pillar growth and valuation breakdown. IMDX trades at $1.66 (N/M Forward P/E, -1883.2% operating margin) versus SYBX at $0.56 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While IMDX currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. SYBX 34.6/100 SELL), SYBX captures the overall institutional head-to-head verdict (2–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -1883.2% operating margin) and revenue trajectory (-100.0% vs. +115.0% YoY).
  • Technical & Structure Timing Caution: IMDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9); meanwhile SYBX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 16.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IMDX vs SYBX
IMDX NASDAQ
Insight Molecular Diagnostics Inc. Common Stock
In Vitro & In Vivo Diagnostic Substances
$1.66
+4.4% 1D
Market Cap $52.1M
TTM Revenue $2.0M
Forward P/E N/M
Beta / 30D Vol 2.91β · 76% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 50.0 Fund 40.0 Flow 58.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.7%), weak momentum, RSI 22
RSI-14: 21.9 · SMA20: $2.51 · SMA50: $3.10
SYBX NASDAQ Head-to-Head Winner
Synlogic, Inc. Common Stock
Pharmaceutical Preparations
$0.56
-50.0% 1D
Market Cap $13.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.68β · 173% Vol
Unified Composite Score
34.6 / 100 SELL
Tech 40.0 Fund 44.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.1%), weak momentum, RSI 17
RSI-14: 16.7 · SMA20: $1.14 · SMA50: $1.31

6-Pillar Scorecard Institutional Category Breakdown (IMDX 3 – 2 SYBX)

Columns: Metric · IMDX · SYBX
1. Valuation Multiples IMDX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 18.8x N/M
2. Growth & Scale IMDX
Revenue Growth (YoY) +115.0% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.0M N/A
Market Cap $52.1M $13.1M
3. Profitability & Quality SYBX
Gross Margin 55.6% N/A
Operating Margin -1883.2% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -23603.1% -27.5%
4. Balance Sheet & Cash Flow IMDX
Cash Generation (TTM) -$31M -$3.3M
Cash Flow Margin N/A N/A
Net Cash / Leverage $15M Net Cash $0.88 Book/Sh · -27.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SYBX
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 99.4% (12th %ile) N/A (N/A)
Put/Call OI Skew 0.08x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IMDX (5) vs SYBX (2)
Institutional Metric IMDX SYBX Criterion Row Edge
Market Capitalization
Scale
$52.1M $13.1M Larger Scale IMDX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+115.0% -100.0% Higher Growth IMDX
Operating Margin (TTM)
Profitability
-1883.2% 0.0% Higher Margin SYBX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-23603.1% -27.5% Higher ROE SYBX
52-Week Range Position
Momentum
3% ($2–$8) 0% ($1–$2) Stronger Trend IMDX
Beta / 30D Volatility
Risk Regime
2.91β · 76% Vol 1.68β · 173% Vol Lower Realized Risk IMDX
Unified Institutional Score
Composite Signal
45.5 / 100 (HOLD) 34.6 / 100 (SELL) Higher Composite IMDX
Trailing 12M Revenue (USD)
Operating Scale
$2.0M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
55.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($15M Net Cash) -$3.3M ($0.88 Book/Sh · -27.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IMDX +78.63 pp
IMDX: +29.54% · SYBX: -49.09%
3M Horizon IMDX +63.22 pp
IMDX: -2.84% · SYBX: -66.06%
6M Horizon IMDX +63.22 pp
IMDX: -2.84% · SYBX: -66.06%
1Y Horizon IMDX +63.22 pp
IMDX: -2.84% · SYBX: -66.06%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IMDX Revenue SYBX Revenue IMDX Op. Margin SYBX Op. Margin Margin Leader
FY2018 N/A $0M N/A -2032.9% SYBX
FY2019 N/A $0M N/A -2446.4% SYBX
FY2020 $0M $0M -2443.3% -11094.7% IMDX
FY2021 $0M $0M -2444.3% -3464.4% IMDX
FY2022 $0M $0M -1878.6% -5713.5% IMDX
FY2023 $0M $0M -1672.4% -1636.3% SYBX
FY2024 $0M $0M -3245.1% -511875.0% IMDX
FY2025 $0M N/A -1260.8% N/A IMDX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IMDX BREAKDOWN
117d in phase · OBV DISTRIBUTION
Current IV 99.4%
IV Percentile 12th %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IMDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SYBX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYBX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IMDX Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $52.1M market capitalization and -1883.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SYBX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $13.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IMDX vs SYBX Key Questions & Quantitative Answers

As of Nov 19, 2026, Synlogic, Inc. (SYBX) captures the overall head-to-head institutional edge over Insight Molecular Diagnostics Inc. (IMDX) on higher Unified Composite conviction (34.6/100 SELL vs. 45.5/100 HOLD) after splitting the core matrix 2–5 (led by Profitability & Quality, Options & Positioning), while IMDX wins 3–2 across the 6-pillar growth and valuation breakdown. IMDX trades at $1.66 (N/M Forward P/E, -1883.2% operating margin) versus SYBX at $0.56 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While IMDX currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. SYBX 34.6/100 SELL), SYBX captures the overall institutional head-to-head verdict (2–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -1883.2% operating margin) and revenue trajectory (-100.0% vs. +115.0% YoY). Technical & Structure Timing Caution: IMDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9); meanwhile SYBX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 16.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IMDX leads the Growth & Scale pillar: IMDX posts +115.0% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (55.6% gross margin, -1883.2% operating margin), compared with SYBX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IMDX cumulative revenue shifted N/A while SYBX shifted N/A. In operating R&D and SG&A reinvestment, IMDX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SYBX.

IMDX screens cheaper on headline valuation multiples. IMDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.8x EV/Revenue (unreported FCF margin), whereas SYBX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMDX (-23603.1% ROE) versus SYBX (-27.5% ROE) capital efficiency.

In options market volatility and institutional positioning, IMDX carries 99.4% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.91β · 76% Vol realized risk). By comparison, SYBX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.68β · 173% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.